NHS Blood and Transplant

Discrimination is the biggest career obstacle for women of colour in the NHS – new research

Retrieved on: 
Tuesday, October 3, 2023
Blood pressure, Workforce, Leadership, NHS Blood and Transplant, Fawcett Society, Blood, Saint Andrew's Society, Workplace, Runnymede, Woman, Research, Transplant, England, Interface (computing), Literature, Runnymede Trust, Patient, Population, Racism, NHS England, NHS, Smoking, Nursing, Management

That same month, Michelle Cox, a healthcare manager and senior nurse, won a case against NHS England and NHS Improvement Commissioning in Manchester.

Key Points: 
  • That same month, Michelle Cox, a healthcare manager and senior nurse, won a case against NHS England and NHS Improvement Commissioning in Manchester.
  • According to NHS data from 2021, black and minority ethnic women are the most likely of all NHS staff groups to experience discrimination from patients or colleagues.
  • My doctoral research looks at the obstacles black and minority ethnic women face in the NHS in terms of career development.

The barriers to career progression

    • I identified eight barriers or drivers (often two sides of the same coin) to career progression for this group.
    • These are: systemic discrimination; leadership and organisational cultures; recruitment and talent management; policies; training; monitoring and accountability; work-life balance; and support.
    • In 2016, minority ethnic NHS staff were 1.56 times more likely to enter formal disciplinary processes than white staff.
    • And they are three times more likely than their peers to think regularly about leaving their jobs.

How discrimination is compounded

    • In the UK, this compounded discrimination is further exacerbated by, among other things, being a migrant or having a non-standard British accent.
    • Accent discrimination can lead to employees receiving poorer pay, having limited access to professional networks, or fewer chances of promotion.
    • Here too, it can see people more likely to leave their jobs.
    • This often has a negative impact on an employee’s mental wellbeing and physical health too.

Providing certainty on how we enforce the laws we regulate

Retrieved on: 
Friday, December 16, 2022
NHS, Heart, Time, Blog, List, NHS Blood and Transplant, Compliance, Police, Telecommunication, Blood, Public sector, ICO, Reading, Department, Government, UK Government G-Cloud, Cryptocurrency, Property management, Management

Until today, we would normally publish enforcement notices, fines and summaries of our audit reports on our website.

Key Points: 
  • Until today, we would normally publish enforcement notices, fines and summaries of our audit reports on our website.
  • While fines may grab peoples attention, every one of these reprimands represents a time we have taken action to raise data protection standards.
  • This will provide certainty to businesses and organisations in what the law requires from them and has already been set out in our ICO25 regulatory approach.
  • With any pilot, we will be measuring the success of our revised approach and the improvements we hope to see.

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Retrieved on: 
Wednesday, September 28, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Science, Institute, Half-life, Clinical research, NHS Blood and Transplant, Safety, Bleeding, Corporation, Pfeiffer v Deutsches Rotes Kreuz, U.S. Securities and Exchange Commission, International Red Cross and Red Crescent Movement, Antibody, Company, Fetal hemoglobin, Pharmacology, Degenerative disease, Hematology, Forward-looking statement, Patient, Pregnancy, Lists of diseases, Concomitant, Male, Transfusion medicine, Nasdaq, Miscarriage, Stillbirth, Translational medicine, Neonatal alloimmune thrombocytopenia, Thrombocytopenia, Death, Research, Biotechnology, Fraunhofer Society, SEC, University, Absorption, Placenta, Human platelet antigen, Fetus, Vaccine, Generic drug, Risk management, Pharmaceutical industry

Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
  • These preliminary results continue to support our projected effective target therapeutic concentrations for the prevention of maternal HPA-1a alloimmunization by RLYB212.
  • Consistent with previously reported data, these preliminary results showed acceptable safety and tolerability with no serious adverse events.
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Who is Hussain: World Record Smashed as British Charity Recruits over 37,000 Blood Donors On Single Day

Retrieved on: 
Saturday, September 17, 2022
Gulf Coast Regional Blood Center, Red, Social justice, Transplant, Blood, International Red Cross and Red Crescent Movement, Partnership, Calendar, NHS Blood and Transplant, History, Bleeding, Volunteering, Hospital, Nightclub, Pharmaceutical industry, Medical device

World record broken for the most blood donations in one calendar day, across 27 countries in over 350 venues worldwide.

Key Points: 
  • World record broken for the most blood donations in one calendar day, across 27 countries in over 350 venues worldwide.
  • This campaign and world record come when there is an acute need for blood and shortages in many countries.
  • LONDON, Sept. 17, 2022 /PRNewswire/ -- Today, social justice charity, Who is Hussain, has announced that they have broken the world record for the largest blood drive in history.
  • Authenticated by the Official World Records, the total number of blood donations was 37,018, beating the previous record of 34,723 set in 2020.

Who is Hussain: World Record Smashed as British Charity Recruits over 37,000 Blood Donors On Single Day

Retrieved on: 
Saturday, September 17, 2022
Gulf Coast Regional Blood Center, Red, Social justice, Transplant, Blood, International Red Cross and Red Crescent Movement, Partnership, Calendar, NHS Blood and Transplant, History, Bleeding, Volunteering, Hospital, Nightclub, Pharmaceutical industry, Medical device

World record broken for the most blood donations in one calendar day, across 27 countries in over 350 venues worldwide.

Key Points: 
  • World record broken for the most blood donations in one calendar day, across 27 countries in over 350 venues worldwide.
  • This campaign and world record come when there is an acute need for blood and shortages in many countries.
  • LONDON, Sept. 17, 2022 /PRNewswire/ -- Today, social justice charity, Who is Hussain, has announced that they have broken the world record for the largest blood drive in history.
  • Authenticated by the Official World Records, the total number of blood donations was 37,018, beating the previous record of 34,723 set in 2020.

British Charity Leads Campaign to Break World Blood Donation Record to Save Lives

Retrieved on: 
Tuesday, August 23, 2022
Zhang Dayi, Transplant, Awareness, Calendar, Council, NHS Blood and Transplant, NHS, Blood, World Blood Donor Day, Social justice, Partnership, Community engagement, Council of the Notariats of the European Union, Muhammad, Pharmaceutical industry, Medical device

LONDON, Aug. 23, 2022 /PRNewswire/ -- On Saturday 27 August, social justice charity Who is Hussain will attempt to break the world record for the most blood donations in one calendar day.

Key Points: 
  • LONDON, Aug. 23, 2022 /PRNewswire/ -- On Saturday 27 August, social justice charity Who is Hussain will attempt to break the world record for the most blood donations in one calendar day.
  • #GlobalBloodHeroes Dayis a worldwide campaign to save lives and build greater awareness about donating blood.
  • Just one blood donation can help save three lives.
  • The campaign hopes to save the lives of 150,000 people at a time when blood supplies are being challenged.

Orbus Software Delivers Record 700%+ Cloud Growth Driven by Demand for SaaS Enterprise Transformation Platform

Retrieved on: 
Wednesday, February 9, 2022
Technology, Software, Industry, Senior, Growth, Jacobs Engineering Group, NHS Blood and Transplant, Bank of Montreal, Saab, Solution, ServiceNow, CIB Bank, IKEA, Software as a service, Architecture, Mastercard, Technology, Brisbane Airport, Microsoft, CEO, Adoption, AstraZeneca, Intact, Dell, Schroders, Ecosystem, Software, Carbon, BP, Bank, SourceAmerica, Fulton Financial Corporation, Christiana Care Health System, ARR, Network equipment, Management, New York Power

As a leading provider of cloud solutions for digital transformation, Orbus Software has seen a record ARR growth of 40%+ in 2021, driven by 700%+ ARR increase in demand for its iServer365 SaaS enterprise transformation platform.

Key Points: 
  • As a leading provider of cloud solutions for digital transformation, Orbus Software has seen a record ARR growth of 40%+ in 2021, driven by 700%+ ARR increase in demand for its iServer365 SaaS enterprise transformation platform.
  • The company added over 100 customers globally in 2021, reflecting the growing demand for SaaS enterprise transformation platforms.
  • Michael DOnofrio, CEO, Orbus Software, commented: Digital transformation is now a critical imperative for all business and government leaders.
  • Orbus Software is a global enterprise software vendor and a recognized leading provider of cloud solutions for digital transformation.

Rotherham Metropolitan Borough Council Modernises Operations with 8x8 XCaaS™

Retrieved on: 
Monday, December 6, 2021
Networks, VoIP, Technology, Telecommunications, Software, EGHT, NHS Blood and Transplant, API, Perception, EMEA, Rotherham Metropolitan Borough Council, City centre, Time, Microsoft Teams, NHS, CCAA Men's Basketball Tournament, NYSE, Compliance, Unified communications, Human, Essex County Fire and Rescue Service, KMPT, Solution, Unified communications as a service, Microsoft, Medway NHS Foundation Trust, SLA, Global, Government Digital Service, COVID 19, Patient safety, Human voice, Twitter, View, Communication, 8x8, ICT, NHS National Services Scotland, LinkedIn, Federal Protective Service (United States), London boroughs, Kent and Medway NHS and Social Care Partnership Trust, Buckinghamshire Council, Public sector, COVID, Mobile phone, Renewable energy, Online shopping, Video game console

8x8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform provider, announced that Rotherham Metropolitan Borough Council has deployed 8x8 XCaaS (eXperience Communications as a Service) to enhance its communications with approximately 260,000 residents in Rotherham.

Key Points: 
  • 8x8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform provider, announced that Rotherham Metropolitan Borough Council has deployed 8x8 XCaaS (eXperience Communications as a Service) to enhance its communications with approximately 260,000 residents in Rotherham.
  • The Rotherham Metropolitan Borough Council deployment reflects the wider success 8x8 has experienced within the public sector in the UK and Ireland this year:
    8x8 XCaaS is now deployed across more than one third of Londons boroughs.
  • 8x8 XCaaS provides Rotherham Metropolitan Borough Council with the capabilities needed for their employees to communicate and collaborate from anywhere while delivering a differentiated level of citizen experience.
  • 8x8, 8x8 XCaaS, eXperience Communications as a Service, and 8x8 Global Reach are trademarks of 8x8, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005233/en/

Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Retrieved on: 
Wednesday, December 1, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, NHS Blood and Transplant, Day, Pharmacology, Placenta, Safety, EudraCT, Forward-looking statement, Death, Fetus, Fetal hemoglobin, Stillbirth, Clinical trial, SEC, University, Lists of diseases, Male, Institute, Thrombocytopenia, Transfusion medicine, Mother, Human platelet antigen, Pregnancy, Nasdaq, Research, Clinical research, Risk, Corporation, Neonatal alloimmune thrombocytopenia, Fraunhofer Society, Biotechnology, Hematology, Bleeding, Antibody, Degenerative disease, FDA, Miscarriage, European Medicines Agency, International Red Cross and Red Crescent Movement, Food, Translational medicine, Pharmaceutical industry, Medical device, Vaccine, FNAIT, Rallybio, FNAIT, RALLYBIO

RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Key Points: 
  • RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
  • We are both pleased with the RLYB211 findings and excited to move into the next phase of our FNAIT program by advancing RLYB212.
  • These data support Rallybios first-in-human clinical trial of its lead candidate RLYB212, a novel human monoclonal anti-HPA-1a antibody which has the same mechanism of action as RLYB211.
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems

Retrieved on: 
Thursday, July 30, 2020
Biotechnology, Hospitals, Health, Cardiology, Medical Supplies, Blood, Transfusion medicine, Branches of biology, Body fluids, BTS, Blood transfusion, Hong Kong Red Cross, Platelet, NHS Blood and Transplant, Hong Kong

Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.
  • The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and private, in Hong Kong.
  • The Hong Kong Red Cross BTS is a member of the influential Asia Pacific Blood Network (APBN) and a key opinion leader globally.
  • The tender award builds upon the prior experience of the Hong Kong Red Cross BTS with the INTERCEPT Blood System for platelets.